The cooperation with the FDA suggests that Gilead Sciences is responsive to regulatory requirements, which is generally positive. However, the nature of the FDA inquiry is not specified, so the impact on the stock price is uncertain. The news could be interpreted both positively, as a sign of transparency and good governance, or negatively, if investors speculate that the inquiry might lead to unfavorable findings. Therefore, a neutral score is given until more details emerge.